View of Concizumab: A Subcutaneous Innovation in Hemophilia A and B—Targeting Factor VIII/IX Deficiency and Inhibitor Management

Return to Article Details Concizumab: A Subcutaneous Innovation in Hemophilia A and B—Targeting Factor VIII/IX Deficiency and Inhibitor Management Download Download PDF